Cynomolgus PCSK9 Protein
- Known as:
- Cynomolgus PCSK9 Protein
- Catalog number:
- PC9-C5223
- Product Quantity:
- 1mg
- Category:
- -
- Supplier:
- acrobyosystems
- Gene target:
- Cynomolgus PCSK9 Protein
Related genes to: Cynomolgus PCSK9 Protein
- Gene:
- PCSK9 NIH gene
- Name:
- proprotein convertase subtilisin/kexin type 9
- Previous symbol:
- HCHOLA3
- Synonyms:
- NARC-1, FH3
- Chromosome:
- 1p32.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-05-13
- Date modifiied:
- 2019-04-23
Related products to: Cynomolgus PCSK9 Protein
Related articles to: Cynomolgus PCSK9 Protein
- Cholesterol pathways may influence head and neck squamous cell carcinoma (HNSCC) progression, but evidence on prognosis is inconsistent. We used Mendelian randomization (MR) to test whether genetically proxied inhibition of major LDL-C-lowering drug targets and circulating lipid traits affects overall survival (OS) in HPV-positive and non-HPV driven HNSCC. - Source: PubMed
Publication date: 2026/07/02
Cheng DanniHueniken KatrinaHou TianzhichaoShu TaoEspin-Garcia OsvaldoDudding TomGormley MarkMcKay James Dde Almeida John RHope Andrew JSpreafico AnnaHuang Shao HuiSchroeder LeaWaterboer TimHayes D NeilVirani ShamaBrennan PaulPring MirandaOlshan Andrew FDiergaarde BrendaMacfarlane Gary JLagiou PagonaLagiou AretiPolesel JerryAgudo AntonioAlemany LaiaAhrens WolfgangHealy Claire MConway David ICanova CristinaHolcatova IvanaRen JianjunZhao YuHung Rayjean JMondul Alison MXu WeiLiu Geoffrey - Abdominal aortic aneurysm (AAA) rupture is an important cause of death worldwide, with no effective drug therapies currently available. PCSK9 (proprotein convertase subtilisin/kexin type 9) regulates LDL-C (low-density lipoprotein-cholesterol) and modulates vascular inflammation, smooth muscle cell apoptosis, and extracellular matrix remodeling, all implicated in AAA pathogenesis. - Source: PubMed
Publication date: 2026/07/02
Wesley Callan DThanigaimani ShivshankarKhan AbidGolledge Jonathan - Muscle symptoms are common with statin therapy, and reduced plasma coenzyme Q10 (CoQ10) has been proposed as a potential mechanism. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are widely used in patients with statin intolerance or severe hypercholesterolemia, including familial hypercholesterolemia (FH), but their effects on plasma CoQ10 remain unclear. - Source: PubMed
Publication date: 2026/06/19
Tada HayatoTakeji YasuakiTakamura Masayuki - Although the safety profile of lipid-lowering therapies (LLTs) is known, there are no comprehensive comparative assessments. We aimed to compare the risk of muscle-related events, diabetes, liver dysfunction, and cognitive disorders among LLTs through a network meta-analysis. - Source: PubMed
Publication date: 2026/06/24
Xie SiningGalimberti FedericaOlmastroni ElenaCatapano Alberico LCasula Manuela - Chronic kidney disease (CKD) affects approximately 14% of adults worldwide, and CKD independently contributes to cardiovascular risk. Hereby, we provide a narrative review of cholesterol-lowering therapies for people with CKD. Abnormal levels of cholesterol and triglycerides are common in CKD and contribute to cardiovascular risk beyond common risk factors like older age, hypertension and diabetes, although the role of cholesterol and triglycerides in kidney disease progression remains uncertain. 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors (statins), alone or combined with ezetimibe, are the most extensively studied treatment in reducing cholesterol and lipids in CKD. Large randomised controlled trials (RCTs) and meta-analyses show statins reduce cardiovascular events and death in CKD, but not in people requiring dialysis despite similar cholesterol-lowering effects. Statins may also improve kidney function but have not demonstrated a benefit in reducing kidney failure. Current clinical guidelines recommend statins, with or without ezetimibe, for most adults with CKD, with therapy individualised based on age, kidney function and cardiovascular risk. However, guidelines in CKD do not indicate any cholesterol targets to guide escalation of treatments. Newer therapies, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and small interfering RNA (eg, inclisiran) demonstrated cardiovascular benefit in the general population, but evidence in CKD is limited. Further research on these therapies is needed to define their role in improving cardiovascular and kidney outcomes in people with CKD. - Source: PubMed
Publication date: 2026/07/01
Tunnicliffe David JKrishnasamy RathikaStrippoli Giovanni Fm